Exploring 12 Analyst Recommendations for Cigna Group on March 4, 2024
An in-depth analysis of 12 analyst recommendations for Cigna Group (NYSE: CI) in the past three months showcases a variety of sentiments ranging from bullish to bearish. These recent ratings and price targets offer valuable insights into the changing perspective on the company.
________________________________________
Analyst Ratings Overview:
– Bullish Sentiment: Out of the total ratings, 3 were deemed Bullish, 6 Somewhat Bullish, and 3 Indifferent. There were no Somewhat Bearish or Bearish ratings.
Recent Changes:
– In the last 30 days, there were no new Bullish ratings, 2 new Somewhat Bullish ratings, and no changes in other categories compared to the previous month.
Price Targets:
– Analysts have set an average 12-month price target for Cigna Group at $361.67, with a high estimate of $392.00 and a low estimate of $334.00. This average target represents a 4.15% increase from the previous average target of $347.25.
________________________________________
Detailed Analyst Actions:
– Erin Wright (Morgan Stanley): Upgraded the rating to Overweight with a price target of $392.00 from $382.00.
– Sarah James (Cantor Fitzgerald): Maintained Overweight with a price target of $372.00 and upgraded another Overweight rating to $372.00 from $334.00.
– Stephen Baxter (Wells Fargo): Upgraded the rating to Equal-Weight with a price target of $348.00 from $334.00.
– Ann Hynes (Mizuho): Upgraded the rating to Buy with a price target of $370.00 from $360.00.
– Frank Morgan (RBC Capital): Upgraded the rating to Outperform with a price target of $354.00 from $327.00.
– George Hill (Deutsche Bank): Upgraded the rating to Buy with a price target of $370.00 from $355.00.
– Michael Wiederhorn (Oppenheimer): Maintained Outperform with a price target of $360.00.
– Lance Wilkes (Bernstein): Announced Outperform with a price target of $372.00.
________________________________________
For more detailed information on analyst ratings and forecasts, consider consulting reliable sources such as TipRanks, MarketBeat, WSJ, MarketWatch, and Yahoo Finance.
CI Stock Shows Strong Performance, Trading Near 52-Week Highs and Above Moving Average
On March 4, 2024, CI stock had a strong performance, trading near the top of its 52-week range and above its 200-day simple moving average. This indicates positive price momentum for the stock, suggesting that it may continue to see gains in the near future. The price of CI shares increased by $3.97 since the market last closed, representing a 1.19% rise. The stock closed at $336.93, showing a healthy increase from the previous trading session. However, it is important to note that the stock dropped $0.93 in after-hours trading, which may indicate some volatility in the stock price. Investors should continue to monitor the stock closely to see if it can sustain this positive momentum in the days ahead.
CI Stock Performance Analysis: Revenue Up, Net Income and EPS Down in 2024
On March 4, 2024, investors were closely watching the stock performance of CI, a leading company in the healthcare industry. According to data from CNN Money, CI reported a total revenue of $195.19 billion for the past year, with a quarterly revenue of $51.08 billion. This represents an 8.42% increase in total revenue since last year, while revenue has remained flat since the last quarter.
Despite the increase in total revenue, CI’s net income saw a decline over the past year. The company reported a net income of $5.16 billion for the past year, with a quarterly net income of $1.03 billion. This represents a 22.56% decrease in net income since last year, although net income has held flat since the last quarter.
Earnings per share (EPS) for CI also saw a decline over the past year. The company reported an EPS of $17.39 for the past year, with a quarterly EPS of $3.49. This represents an 18.33% decrease in EPS since last year, although EPS has held flat since the last quarter.
Overall, CI’s stock performance on March 4, 2024, may have been influenced by the mixed financial results reported by the company. While total revenue saw an increase, both net income and EPS saw declines over the past year. Investors may have been cautious in their assessment of CI’s performance.
